top of page
Optimism for Factor XI in stroke unchanged despite expected BMY/JNJ failure in heart attacks
Don't write off Factor XIs despite heart attack and AF failures
With the expected failure of BMY/JNJ’s Factor XI milvexian in LIBREXIA-ACS (heart attack) trial we reiterate our contrarian view that all hope may not be lost for the use of Factor XIs in the stroke prevention despite BAYN’s asundexian’s 2023 failure to reduce strokes in OCEANIC-AF. Ahead of BAYN year-end Factor XI OCEANIC-STROKE readout, we remain optimistic for BMY/JNJ Factor XI milvexian phase III LIBREXIA-STROKE in 2026.
bottom of page